Clinical Trial: A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy

U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT07548060) titled 'A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy' on Feb. 05.

Brief Summary: Efficacy and Safety of Sacituzumab Tirumotecan Combined with Furmonertinib in Patients with Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy.

Study Start Date: Feb. 01

Study Type: INTERVENTIONAL

Condition: NSCLC Stage IV EGFR Gene Mutation

Intervention: DRUG: sacituzumab tirumotecan

Sacituzumab tirumotecan 5 mg/...